8-K: Climb Bio Restructures RA Capital Stake with Warrants

Climb Bio, Inc. entered an agreement with RA Capital Management, L.P. to exchange 20.44 million common shares for pre-funded warrants, adjusting its capital structure and RA Capital's beneficial ownership.

Summary

• Climb Bio, Inc. entered into an exchange agreement with RA Capital Management, L.P. and an affiliated entity (the Exchanging Stockholder) on December 11, 2025.
• The Exchanging Stockholder agreed to exchange 20,440,000 shares of Climb Bio's common stock for a pre-funded warrant to purchase an aggregate of 20,440,000 shares of common stock.
• The pre-funded warrant has an exercise price of $0.0001 per share and is exercisable at any time after issuance.
• The transaction is expected to close on December 11, 2025, subject to customary closing conditions.
• Immediately following the consummation of the exchange and retirement of the exchanged shares, there will be 47,744,435 shares of common stock issued and outstanding.
• After giving effect to the exchange, RA Capital, the Exchanging Stockholder, and their affiliates will beneficially own approximately 23.0% of the company's outstanding voting power.
• RA Capital and its affiliates have agreed to vote all securities beneficially owned by them in excess of 33.0% of the total voting power in proportion to and in accordance with the vote of all other stockholders.
• The Exchanging Holder will not be entitled to exercise any portion of the pre-funded warrant if it would result in their aggregate beneficial ownership exceeding 33.00% of the outstanding common stock immediately after such exercise.
• RA Capital may exchange additional shares for pre-funded warrants in the future, subject to certain terms and the company's written consent.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the transaction does not bring new capital, it represents a strategic capital structure adjustment that reduces immediate outstanding common shares and solidifies the long-term commitment of a major institutional investor (RA Capital) through pre-funded warrants. The governance aspects related to voting limitations for RA Capital are also a neutral to slightly positive factor.

Positives

• The immediate retirement of 20,440,000 common shares reduces the number of issued and outstanding common stock to 47,744,435, which can be viewed as a capital structure optimization.
• The transaction allows Climb Bio to retain a significant institutional investor (RA Capital) with a long-term economic interest through pre-funded warrants, potentially signaling continued investor confidence.
• The voting agreement, which limits RA Capital's voting influence above 33.0% by requiring proportional voting, may enhance corporate governance perception for other shareholders.
• The exchange is structured to qualify for the Section 3(a)(9) exemption under the Securities Act, simplifying the regulatory process for the issuance of the warrants.

Negatives

• While the initial effect is a reduction in outstanding common stock, the pre-funded warrants represent a future potential re-issuance of 20,440,000 shares upon exercise, which could increase the outstanding share count again.
• The 33.0% beneficial ownership limitation on warrant exercise restricts RA Capital's flexibility in fully converting their warrant position into common stock, potentially impacting their liquidity or control strategy.
• The transaction is an exchange of existing equity for warrants and does not bring new capital into the company.

Risks

• The 33.0% beneficial ownership limitation on the exercise of the pre-funded warrants could restrict RA Capital's ability to fully convert their investment into common stock, potentially affecting their investment strategy or exit options.
• The reliance on the Section 3(a)(9) exemption under the Securities Act requires strict adherence to conditions, including no remuneration for soliciting the exchange, and any failure to meet these conditions could have regulatory implications.
• Future market conditions or changes in the company's stock price could impact the value and exercisability of the pre-funded warrants.

Future Outlook

The transactions contemplated by the Exchange Agreement are expected to close on December 11, 2025, subject to customary closing conditions. Following the agreement date, RA Capital may exchange additional shares of Common Stock beneficially owned by it or its affiliates for Pre-Funded Warrants, subject to certain terms and the Company’s written consent.

Industry Context

This type of capital structure adjustment, involving the exchange of common stock for pre-funded warrants, is a sophisticated financial strategy often employed by large institutional investors in the biotech sector. It allows a significant shareholder like RA Capital to manage its beneficial ownership stake, potentially to avoid triggering certain regulatory thresholds or to optimize its investment structure, while maintaining a long-term economic interest in the company. This approach is common in industries where long-term capital commitment and strategic investor relations are crucial.

Corporate Governance

Related Party Transactions

• The exchange agreement is with RA Capital Management, L.P. and an affiliated entity, which is a significant beneficial owner of the company's common stock. This constitutes a related party transaction.

Stakeholder Impact

• **Shareholders:** The immediate reduction in outstanding common shares could be viewed positively. However, the future exercise of the pre-funded warrants could lead to an increase in the share count. The voting agreement provides clarity on the influence of a major investor.
• **RA Capital Management, L.P.:** Their ownership structure is adjusted from common stock to pre-funded warrants, allowing them to maintain economic exposure while managing beneficial ownership percentages. Their voting power is capped at 33.0% for proportional voting on excess shares, and their warrant exercise is also limited by a 33.0% beneficial ownership threshold.

Next Steps

• Consummation of the exchange transaction on December 11, 2025, subject to customary closing conditions.
• Potential future exchanges of additional common stock for pre-funded warrants by RA Capital, subject to the company's written consent.

Key Dates

Recommendation

The transaction represents a strategic capital structure adjustment and investor relationship management rather than a direct indicator of operational performance. The immediate reduction in outstanding shares is a positive structural change, and the retention of a key institutional investor like RA Capital is generally favorable. However, the potential future re-issuance of shares upon warrant exercise and the limitations on RA Capital's full conversion flexibility warrant a cautious approach. Investors should hold to observe the long-term implications of this capital restructuring and the company's operational progress, as this filing primarily addresses a financial engineering move rather than core business performance.

Keywords

Biotech, Warrants, Capital Structure, SEC Filing, RA Capital, Common Stock, Exchange Agreement, Pre-Funded Warrant, Beneficial Ownership, Corporate Governance